Cahill Represents Financing Sources in Valeant - Biovail Merger
Date: 09/28/10
Cahill represented the Administrative Agent and Arrangers, in connection with $2,750,000,000 of senior secured credit facilities to finance the merger of Valeant Pharmaceuticals International and Biovail Corporation and related refinancing of certain existing indebtedness.
Cahill also represented the joint book-running managers in a Rule 144A/Reg S offering of two tranches of Senior Notes by Valeant Pharmaceuticals International, consisting of $500,000,000 of 6.75% Senior Notes due 2018 and $700,000,000 of 7.00% Senior Notes due 2020. A portion of the proceeds of the Senior Notes was used to finance the merger.